| Methods |
7‐day washout; 4‐week single‐blind placebo baseline; inclusion criteria= mean sitting DBP 95‐115 mm Hg of week 2 and week 4 baseline recordings with difference in these means </= 7 mm Hg, mean sitting SBP had to be < 210 mm Hg at each baseline visit; 12‐week double‐blind treatment |
| Participants |
Enalapril 5 mg: n=144(94 males,50 females); mean age=56.1(10.0) years; baseline sitting SBP=155.2 mm Hg, DBP=101.6(5.5) mm Hg;
Placebo: n=150(104 males,46 females); mean age=55.8(11.4) years; baseline sitting SBP=155.4 mm Hg, DBP=101.6(5.6) mm Hg |
| Interventions |
Enalapril 5 mg once daily;
Placebo;
administered between 6:30 AM and 10:00 AM |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported; endpoint BP reported; endpoint SD not reported; imputed overall trial mean SD of change for SBP and DBP; BP data from Table 2, p. 26; Jadad score=4; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
